Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. This decline includes a sell-off earlier this ...

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 ... U.S. Customs and Border Protection. Image source: Official White House photo by Shealah Craighead. The president-elect has singled out some ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...

Eli Lilly's operational performance is strong ... As an example, we need only look at the image below. This shows the company's current pipeline of drugs that are in either Phase 1, Phase 2 ...

The Investment Committee give you their top stocks to watch for the second half.

Image Source: Zacks Investment Research Over the last year, Eli Lilly’s stock is up a very respectable +25% which has roughly matched the S&P 500 while Novo Nordisk shares are down a lackluster ...